Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

NEW YORK, Oct. 1 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

Intra-Cellular Therapies presented preclinical data at the 2nd World Parkinson Congress held in Glasgow, Scotland, demonstrating ITI-002 was effective in improving motor and non-motor behaviors relevant to the treatment of Parkinson's disease. In well-established pre-clinical models of PD, ITI-002 was shown to restore normal motor function when given in combination with L-DOPA; ITI-002 increased the effectiveness of a sub-threshold and a sub-maximal dose of L-DOPA when the compounds were co-administered in unilaterally 6-hydroxy dopamine-lesioned or reserpine-treated mice. This combination resulted in a full restoration of the affected limb use and a re-establishment of normal mobility. ITI-002 also reversed the akinesia and catalepsy induced by the dopamine receptor antagonist haloperidol. In other pre-clinical models, ITI-002 was shown to improve cognitive performance and to increase daytime wakefulness without causing psychomotor stimulation.

"We are pleased to have demonstrated the ability of ITI-002 to improve motor and non-motor behaviors in pre-clinical models relevant to Parkinson's disease. These data suggest ITI-002 may be useful in prolonging the effectiveness and lowering the doses of dopamine replacement therapies, thereby providing for full restoration of motor function without causing troubling side effects in patients with Parkinson's Disease," stated Sharon Mates, Chief Executive Officer of Intra-Cellular Therapies.  "Since ITI-002 acts by enhancing intra-cellular dopamine signaling, ITI-002 also may be useful as a stand-alone treatment early in this disease when residual dopamine is still present.  In addition, patients with Parkinson's disease often suffer co-mor
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ -- ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
(Date:7/11/2014)... , July 11, 2014 EPFL ... announce the appointment of John P. Donoghue . ...   in  Geneva . The new ... Biotech in Geneva , has named ... neuroscientists. John P. Donoghue , founder of Brown ...
(Date:7/11/2014)... July 11, 2014  Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3
... YORK, Oct. 6, 2011 A new invention could ... is a portable, rapid pathogen screener that could ... in processing plants, before it is delivered to the ... as a single bacteria, and is approximately 50 times ...
... 6, 2011 ProteinSimple today announced the launch ... control monitoring of protein-based therapeutics. The iCE3 platform ... conference, October 9-13, 2011, at Amelia Island, FL. ... product purity closely. Imaged capillary electrophoresis (iCE) systems ...
... Luminex Corporation (NASDAQ: LMNX ) announced today that ... – Be The Match to raise awareness of the need ... match for the growing number of patients awaiting life-saving bone ... National Marrow Donor Registry in an effort to assist patients ...
Cached Biology Technology:Breakthrough in Preventing Food-borne Illnesses Wins $20,000 Grand Prize in Global Design Contest 2Breakthrough in Preventing Food-borne Illnesses Wins $20,000 Grand Prize in Global Design Contest 3Breakthrough in Preventing Food-borne Illnesses Wins $20,000 Grand Prize in Global Design Contest 4ProteinSimple Launches New System for Protein Biologics 2Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 2Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 3Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 4
(Date:7/13/2014)... women suggests that experiencing one or more stressful events ... slow the body,s metabolism, potentially contributing to weight gain. ... stressors before giving them a meal consisting of 930 ... measured their metabolic rate how long it took ... took measures of blood sugar, triglycerides, insulin and the ...
(Date:7/13/2014)... available in French . ... international research project, led by the Research Institute of ... that a new oral medication is showing significant progress ... (LCA). Until now, this inherited retinal disease that causes ... has remained untreatable. The study is published today in ...
(Date:7/13/2014)... prospect of more effective treatments for cachexia, a profound ... of all cancer patients, raising their risk of death, ... strategies have been tried to reverse the condition, which ... life-saving treatments, but none have had great success. , ... of Nature , led by Bruce Spiegelman, PhD, ...
Breaking Biology News(10 mins):Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4MUHC researcher unveils novel treatment for a form of childhood blindness 2Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3
... derivative, and was approved for the treatment of neuropathic ... 2002. However, little evidence is available on the effects ... attack period. A recent study by Yanbo Zhang and ... showed that excitatory amino acids and protein kinase C ...
... Ectobius is a major textbook example of an invasive ... region from northernmost Europe to southernmost Africa. Ectobius ... amber that is about 44 million years old, and its lineage ... a shocking new discovery has uprooted that view. In fact, it ...
... stink bugs as pests, especially as the brown marmorated stink ... beneficial, such as Podisus nigrispinus (Dallas), a predatory ... for various insect pests of cotton, soybean, tomato, corn, kale, ... Annals of the Entomological Society of America called ...
Cached Biology News:After a 49-million-year hiatus, a cockroach reappears in North America 2New study may aid rearing of stink bugs for biological control 2
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
KAI 1 (G-2)...
Biology Products: